1a6z › Citations

Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor.

Lebrón JA, Bennett MJ, Vaughn DE, Chirino AJ, Snow PM, Mintier GA, Feder JN, Bjorkman PJ
Cell 93 111-23 (1998)
Cited: 360 times
EuropePMC logo PMID: 9546397

Abstract

HFE is an MHC-related protein that is mutated in the iron-overload disease hereditary hemochromatosis. HFE binds to transferrin receptor (TfR) and reduces its affinity for iron-loaded transferrin, implicating HFE in iron metabolism. The 2.6 A crystal structure of HFE reveals the locations of hemochromatosis mutations and a patch of histidines that could be involved in pH-dependent interactions. We also demonstrate that soluble TfR and HFE bind tightly at the basic pH of the cell surface, but not at the acidic pH of intracellular vesicles. TfR:HFE stoichiometry (2:1) differs from TfR:transferrin stoichiometry (2:2), implying a different mode of binding for HFE and transferrin to TfR, consistent with our demonstration that HFE, transferrin, and TfR form a ternary complex.

Reviews - 1a6z mentioned but not cited (2)

  1. Cis interactions of immunoreceptors with MHC and non-MHC ligands. Held W, Mariuzza RA. Nat Rev Immunol 8 269-278 (2008)
  2. Structure and function of the non-classical major histocompatibility complex molecule MR1. Krovi SH, Gapin L. Immunogenetics 68 549-559 (2016)

Articles - 1a6z mentioned but not cited (6)

  1. Protein-protein docking benchmark version 3.0. Hwang H, Pierce B, Mintseris J, Janin J, Weng Z. Proteins 73 705-709 (2008)
  2. Protein-protein docking using region-based 3D Zernike descriptors. Venkatraman V, Yang YD, Sael L, Kihara D. BMC Bioinformatics 10 407 (2009)
  3. Crystal structure of the murine cytomegalovirus MHC-I homolog m144. Natarajan K, Hicks A, Mans J, Robinson H, Guan R, Mariuzza RA, Margulies DH. J Mol Biol 358 157-171 (2006)
  4. Crystal structure of the N-myristoylated lipopeptide-bound MHC class I complex. Morita D, Yamamoto Y, Mizutani T, Ishikawa T, Suzuki J, Igarashi T, Mori N, Shiina T, Inoko H, Fujita H, Iwai K, Tanaka Y, Mikami B, Sugita M. Nat Commun 7 10356 (2016)
  5. Structural Comparison Between MHC Classes I and II; in Evolution, a Class-II-Like Molecule Probably Came First. Wu Y, Zhang N, Hashimoto K, Xia C, Dijkstra JM. Front Immunol 12 621153 (2021)
  6. Structure of MHC class I-like MILL2 reveals heparan-sulfate binding and interdomain flexibility. Kajikawa M, Ose T, Fukunaga Y, Okabe Y, Matsumoto N, Yonezawa K, Shimizu N, Kollnberger S, Kasahara M, Maenaka K. Nat Commun 9 4330 (2018)


Reviews citing this publication (131)

  1. Balancing acts: molecular control of mammalian iron metabolism. Hentze MW, Muckenthaler MU, Andrews NC. Cell 117 285-297 (2004)
  2. Disorders of iron metabolism. Andrews NC. N Engl J Med 341 1986-1995 (1999)
  3. Hereditary hemochromatosis--a new look at an old disease. Pietrangelo A. N Engl J Med 350 2383-2397 (2004)
  4. Forging a field: the golden age of iron biology. Andrews NC. Blood 112 219-230 (2008)
  5. Iron homeostasis. Andrews NC, Schmidt PJ. Annu Rev Physiol 69 69-85 (2007)
  6. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Eisenstein RS. Annu Rev Nutr 20 627-662 (2000)
  7. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Ghetie V, Ward ES. Annu Rev Immunol 18 739-766 (2000)
  8. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Daniels TR, Bernabeu E, Rodríguez JA, Patel S, Kozman M, Chiappetta DA, Holler E, Ljubimova JY, Helguera G, Penichet ML. Biochim Biophys Acta 1820 291-317 (2012)
  9. The transferrin receptor: role in health and disease. Ponka P, Lok CN. Int J Biochem Cell Biol 31 1111-1137 (1999)
  10. Mechanisms of mammalian iron homeostasis. Pantopoulos K, Porwal SK, Tartakoff A, Devireddy L. Biochemistry 51 5705-5724 (2012)
  11. The roles of iron in health and disease. Lieu PT, Heiskala M, Peterson PA, Yang Y. Mol Aspects Med 22 1-87 (2001)
  12. Brain iron pathways and their relevance to Parkinson's disease. Berg D, Gerlach M, Youdim MB, Double KL, Zecca L, Riederer P, Becker G. J Neurochem 79 225-236 (2001)
  13. Iron homeostasis: insights from genetics and animal models. Andrews NC. Nat Rev Genet 1 208-217 (2000)
  14. Transferrin/transferrin receptor-mediated drug delivery. Li H, Qian ZM. Med Res Rev 22 225-250 (2002)
  15. The intracellular trafficking pathway of transferrin. Mayle KM, Le AM, Kamei DT. Biochim Biophys Acta 1820 264-281 (2012)
  16. The HLA system. Second of two parts. Klein J, Sato A. N Engl J Med 343 782-786 (2000)
  17. Iron and immunity: a double-edged sword. Weiss G. Eur J Clin Invest 32 Suppl 1 70-78 (2002)
  18. Transferrin receptor 1. Aisen P. Int J Biochem Cell Biol 36 2137-2143 (2004)
  19. Functions of nonclassical MHC and non-MHC-encoded class I molecules. Braud VM, Allan DS, McMichael AJ. Curr Opin Immunol 11 100-108 (1999)
  20. Iron metabolism. Aisen P, Wessling-Resnick M, Leibold EA. Curr Opin Chem Biol 3 200-206 (1999)
  21. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Ginzburg Y, Rivella S. Blood 118 4321-4330 (2011)
  22. Physiology and molecular biology of dietary iron absorption. Miret S, Simpson RJ, McKie AT. Annu Rev Nutr 23 283-301 (2003)
  23. The adaptable major histocompatibility complex (MHC) fold: structure and function of nonclassical and MHC class I-like molecules. Adams EJ, Luoma AM. Annu Rev Immunol 31 529-561 (2013)
  24. Haemochromatosis. Brissot P, Pietrangelo A, Adams PC, de Graaff B, McLaren CE, Loréal O. Nat Rev Dis Primers 4 18016 (2018)
  25. The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Kwok JC, Richardson DR, Richardson DR. Crit Rev Oncol Hematol 42 65-78 (2002)
  26. Mechanisms of iron accumulation in hereditary hemochromatosis. Fleming RE, Sly WS. Annu Rev Physiol 64 663-680 (2002)
  27. Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Widera A, Norouziyan F, Shen WC. Adv Drug Deliv Rev 55 1439-1466 (2003)
  28. Hepcidin: regulation of the master iron regulator. Rishi G, Wallace DF, Subramaniam VN. Biosci Rep 35 e00192 (2015)
  29. The regulation of cellular iron metabolism. Chua AC, Graham RM, Trinder D, Olynyk JK. Crit Rev Clin Lab Sci 44 413-459 (2007)
  30. The long history of iron in the Universe and in health and disease. Sheftel AD, Mason AB, Ponka P. Biochim Biophys Acta 1820 161-187 (2012)
  31. Natural history of juvenile haemochromatosis. De Gobbi M, Roetto A, Piperno A, Mariani R, Alberti F, Papanikolaou G, Politou M, Lockitch G, Girelli D, Fargion S, Cox TM, Gasparini P, Cazzola M, Camaschella C. Br J Haematol 117 973-979 (2002)
  32. Iron and carcinogenesis: from Fenton reaction to target genes. Toyokuni S. Redox Rep 7 189-197 (2002)
  33. Hemochromatosis: genetics and pathophysiology. Beutler E. Annu Rev Med 57 331-347 (2006)
  34. Iron metabolism: iron deficiency and iron overload. Andrews NC. Annu Rev Genomics Hum Genet 1 75-98 (2000)
  35. HFE gene variants affect iron in the brain. Nandar W, Connor JR. J Nutr 141 729S-739S (2011)
  36. Iron overload and toxicity: the hidden risk of multiple blood transfusions. Shander A, Cappellini MD, Goodnough LT. Vox Sang 97 185-197 (2009)
  37. Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections? Crux NB, Elahi S. Front Immunol 8 832 (2017)
  38. Iron toxicity as a potential factor in AMD. Wong RW, Richa DC, Hahn P, Green WR, Dunaief JL. Retina 27 997-1003 (2007)
  39. Genetics of haemochromatosis. Bomford A. Lancet 360 1673-1681 (2002)
  40. Hemochromatosis: diagnosis and management. Bacon BR. Gastroenterology 120 718-725 (2001)
  41. Physiology of iron transport and the hemochromatosis gene. Pietrangelo A. Am J Physiol Gastrointest Liver Physiol 282 G403-14 (2002)
  42. Biological and clinical aspects of soluble transferrin receptor. Speeckaert MM, Speeckaert R, Delanghe JR. Crit Rev Clin Lab Sci 47 213-228 (2010)
  43. MHC superfamily structure and the immune system. Maenaka K, Jones EY. Curr Opin Struct Biol 9 745-753 (1999)
  44. Hereditary hemochromatosis. Pietrangelo A. Biochim Biophys Acta 1763 700-710 (2006)
  45. Heme in intestinal epithelial cell turnover, differentiation, detoxification, inflammation, carcinogenesis, absorption and motility. Oates PS, West AR. World J Gastroenterol 12 4281-4295 (2006)
  46. Iron transport. Wessling-Resnick M. Annu Rev Nutr 20 129-151 (2000)
  47. HFE gene: Structure, function, mutations, and associated iron abnormalities. Barton JC, Edwards CQ, Acton RT. Gene 574 179-192 (2015)
  48. Metal transporters and disease. Andrews NC. Curr Opin Chem Biol 6 181-186 (2002)
  49. The macrophage: a cellular factory at the interphase between iron and immunity for the control of infections. Theurl I, Fritsche G, Ludwiczek S, Garimorth K, Bellmann-Weiler R, Weiss G. Biometals 18 359-367 (2005)
  50. Molecular aspects of iron absorption and HFE expression. Parkkila S, Niemelä O, Britton RS, Fleming RE, Waheed A, Bacon BR, Sly WS. Gastroenterology 121 1489-1496 (2001)
  51. The Implication and Significance of Beta 2 Microglobulin: A Conservative Multifunctional Regulator. Li L, Dong M, Wang XG. Chin Med J (Engl) 129 448-455 (2016)
  52. Haemochromatosis in the new millennium. Powell LW, Subramaniam VN, Yapp TR. J Hepatol 32 48-62 (2000)
  53. Hepcidin-ferroportin axis in health and disease. Ginzburg YZ. Vitam Horm 110 17-45 (2019)
  54. Iron homeostasis in breast cancer. Marques O, da Silva BM, Porto G, Lopes C. Cancer Lett 347 1-14 (2014)
  55. Recycling iron in normal and pathological states. Beaumont C, Delaby C. Semin Hematol 46 328-338 (2009)
  56. Conservation and diversification of MHC class I and its related molecules in vertebrates. Hashimoto K, Okamura K, Yamaguchi H, Ototake M, Nakanishi T, Kurosawa Y. Immunol Rev 167 81-100 (1999)
  57. Systemic iron homeostasis and erythropoiesis. Papanikolaou G, Pantopoulos K. IUBMB Life 69 399-413 (2017)
  58. The regulation of hepcidin and its effects on systemic and cellular iron metabolism. Fleming MD. Hematology Am Soc Hematol Educ Program 151-158 (2008)
  59. A structural perspective on MHC class Ib molecules in adaptive immunity. Sullivan LC, Hoare HL, McCluskey J, Rossjohn J, Brooks AG. Trends Immunol 27 413-420 (2006)
  60. Genetic disorders affecting proteins of iron metabolism: clinical implications. Sheth S, Brittenham GM. Annu Rev Med 51 443-464 (2000)
  61. Hemochromatosis gene modifies course of hepatitis C viral infection. Pietrangelo A. Gastroenterology 124 1509-1523 (2003)
  62. The hereditary hemochromatosis gene (HFE): a MHC class I-like gene that functions in the regulation of iron homeostasis. Feder JN. Immunol Res 20 175-185 (1999)
  63. The regulation of mineral absorption in the gastrointestinal tract. Powell JJ, Jugdaohsingh R, Thompson RP. Proc Nutr Soc 58 147-153 (1999)
  64. Molecular mechanisms and regulation of iron transport. Chung J, Wessling-Resnick M. Crit Rev Clin Lab Sci 40 151-182 (2003)
  65. The SLC40 basolateral iron transporter family (IREG1/ferroportin/MTP1). McKie AT, Barlow DJ. Pflugers Arch 447 801-806 (2004)
  66. Hereditary hemochromatosis. Pietrangelo A. Annu Rev Nutr 26 251-270 (2006)
  67. Recent advances in understanding haemochromatosis: a transition state. Robson KJ, Merryweather-Clarke AT, Cadet E, Viprakasit V, Zaahl MG, Pointon JJ, Weatherall DJ, Rochette J. J Med Genet 41 721-730 (2004)
  68. The evaluation of hyperferritinemia: an updated strategy based on advances in detecting genetic abnormalities. Aguilar-Martinez P, Schved JF, Brissot P. Am J Gastroenterol 100 1185-1194 (2005)
  69. Inherited Disorders of Iron Overload. Pantopoulos K. Front Nutr 5 103 (2018)
  70. The liver in regulation of iron homeostasis. Rishi G, Subramaniam VN. Am J Physiol Gastrointest Liver Physiol 313 G157-G165 (2017)
  71. Disorders associated with systemic or local iron overload: from pathophysiology to clinical practice. Sebastiani G, Pantopoulos K. Metallomics 3 971-986 (2011)
  72. Molecular aspects of iron absorption: Insights into the role of HFE in hemochromatosis. Philpott CC. Hepatology 35 993-1001 (2002)
  73. Iron homeostasis and inherited iron overload disorders: an overview. Heeney MM, Andrews NC. Hematol Oncol Clin North Am 18 1379-403, ix (2004)
  74. CD1, tuberculosis, and the evolution of major histocompatibility complex molecules. Shinkai K, Locksley RM. J Exp Med 191 907-914 (2000)
  75. Molecular insights into the pathogenesis of hereditary haemochromatosis. Pietrangelo A. Gut 55 564-568 (2006)
  76. Iron Imports. VI. HFE and regulation of intestinal iron absorption. Fleming RE, Britton RS. Am J Physiol Gastrointest Liver Physiol 290 G590-4 (2006)
  77. Pumping iron: the strange partnership of the hemochromatosis protein, a class I MHC homolog, with the transferrin receptor. Enns CA. Traffic 2 167-174 (2001)
  78. Regulation of mammalian iron homeostasis. Schneider BD, Leibold EA. Curr Opin Clin Nutr Metab Care 3 267-273 (2000)
  79. Structure and dynamics of drug carriers and their interaction with cellular receptors: focus on serum transferrin. Luck AN, Mason AB. Adv Drug Deliv Rev 65 1012-1019 (2013)
  80. Transferrin receptor in tissue and serum: updated clinical significance of soluble receptor. Kohgo Y, Torimoto Y, Kato J. Int J Hematol 76 213-218 (2002)
  81. Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention. Harrison SA, Bacon BR. Med Clin North Am 89 391-409 (2005)
  82. The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of hereditary hemochromatosis. Kawabata H. Int J Hematol 107 31-43 (2018)
  83. HFE gene variants, iron, and lipids: a novel connection in Alzheimer's disease. Ali-Rahmani F, Schengrund CL, Connor JR. Front Pharmacol 5 165 (2014)
  84. Hereditary hemochromatosis: update for 2003. Harrison SA, Bacon BR. J Hepatol 38 Suppl 1 S14-23 (2003)
  85. Intestinal iron absorption: current concepts circa 2000. Andrews NC. Dig Liver Dis 32 56-61 (2000)
  86. Blood iron homeostasis: newly discovered proteins and iron imbalance. Bleackley MR, Wong AY, Hudson DM, Wu CH, Macgillivray RT. Transfus Med Rev 23 103-123 (2009)
  87. The hemochromatosis protein HFE 20 years later: An emerging role in antigen presentation and in the immune system. Reuben A, Chung JW, Lapointe R, Santos MM. Immun Inflamm Dis 5 218-232 (2017)
  88. Hemochromatosis gene in leukemia and lymphoma. Dorak MT, Burnett AK, Worwood M. Leuk Lymphoma 43 467-477 (2002)
  89. HFE gene in primary and secondary hepatic iron overload. Sebastiani G, Walker AP. World J Gastroenterol 13 4673-4689 (2007)
  90. Haemochromatosis. Pietrangelo A. Gut 52 Suppl 2 ii23-30 (2003)
  91. Hereditary hemochromatosis. Ajioka RS, Kushner JP. Semin Hematol 39 235-241 (2002)
  92. The emerging role of the liver in iron metabolism. Sharma N, Butterworth J, Cooper BT, Tselepis C, Iqbal TH. Am J Gastroenterol 100 201-206 (2005)
  93. Molecular insights into mechanisms of iron transport. Andrews NC, Fleming MD, Levy JE. Curr Opin Hematol 6 61-64 (1999)
  94. Age-Related Changes and Sex-Related Differences in Brain Iron Metabolism. Grubić Kezele T, Ćurko-Cofek B. Nutrients 12 E2601 (2020)
  95. Haemochromatosis: understanding the mechanism of disease and implications for diagnosis and patient management following the recent cloning of novel genes involved in iron metabolism. Fletcher LM, Halliday JW. J Intern Med 251 181-192 (2002)
  96. Iron overload: molecular clues to its cause. Kühn LC. Trends Biochem Sci 24 164-166 (1999)
  97. MHC homologs in the nervous system--they haven't lost their groove. Olson R, Dulac C, Bjorkman PJ. Curr Opin Neurobiol 16 351-357 (2006)
  98. Pathogenesis of hereditary hemochromatosis. Fleming RE, Britton RS, Waheed A, Sly WS, Bacon BR. Clin Liver Dis 8 755-73, vii (2004)
  99. The major histocompatibility complex-encoded HFE in iron homeostasis and immune function. Salter-Cid L, Peterson PA, Yang Y. Immunol Res 22 43-59 (2000)
  100. Transferrin as a model system for method development to study structure, dynamics and interactions of metalloproteins using mass spectrometry. Kaltashov IA, Bobst CE, Zhang M, Leverence R, Gumerov DR. Biochim Biophys Acta 1820 417-426 (2012)
  101. Update on iron metabolism and molecular perspective of common genetic and acquired disorder, hemochromatosis. Yun S, Vincelette ND. Crit Rev Oncol Hematol 95 12-25 (2015)
  102. Genetics of hemochromatosis. Cullen LM, Anderson GJ, Ramm GA, Jazwinska EC, Powell LW. Annu Rev Med 50 87-98 (1999)
  103. The haemochromatosis gene: a global perspective and implications for the Asia-Pacific region. Mortimore M, Merryweather-Clarke AT, Robson KJ, Powell LW. J Gastroenterol Hepatol 14 838-843 (1999)
  104. The structure and function of HFE. Drakesmith H, Townsend A. Bioessays 22 595-598 (2000)
  105. Hemochromatosis 1998: is one gene enough? Pietrangelo A. J Hepatol 29 502-509 (1998)
  106. Is genetic screening for hemochromatosis worthwhile? Njajou OT, Alizadeh BZ, van Duijn CM. Eur J Epidemiol 19 101-108 (2004)
  107. Strategies for early diagnosis of haemochromatosis. Niederau C, Strohmeyer G. Eur J Gastroenterol Hepatol 14 217-221 (2002)
  108. The unfolded protein response in hereditary haemochromatosis. de Almeida SF, de Sousa M. J Cell Mol Med 12 421-434 (2008)
  109. Iron, the HFE gene, and hepatitis C. Eisenbach C, Gehrke SG, Stremmel W. Clin Liver Dis 8 775-85, vii-viii (2004)
  110. Review article: the genetic basis of haemochromatosis. Griffiths WJ. Aliment Pharmacol Ther 26 331-342 (2007)
  111. What's new in hemochromatosis. Gochee PA, Powell LW. Curr Opin Hematol 8 98-104 (2001)
  112. Haemochromatosis: an inherited metal and toxicity syndrome. Cox TM, Kelly AL. Curr Opin Genet Dev 8 274-281 (1998)
  113. Liver-gut axis in the regulation of iron homeostasis. Darshan D, Anderson GJ. World J Gastroenterol 13 4737-4745 (2007)
  114. Molecular regulation of hepatic expression of iron regulatory hormone hepcidin. Oates PS, Ahmed U. J Gastroenterol Hepatol 22 1378-1387 (2007)
  115. The enigmatic role of the hemochromatosis protein (HFE) in iron absorption. Chorney MJ, Yoshida Y, Meyer PN, Yoshida M, Gerhard GS. Trends Mol Med 9 118-125 (2003)
  116. Erythropoiesis and transferrin receptors. Moura IC, Hermine O, Lacombe C, Mayeux P. Curr Opin Hematol 22 193-198 (2015)
  117. How mammals acquire and distribute iron needed for oxygen-based metabolism. Rouault TA. PLoS Biol 1 E79 (2003)
  118. The role of MHC class Ib-restricted T cells during infection. Anderson CK, Brossay L. Immunogenetics 68 677-691 (2016)
  119. Broadsheet number 54. Hereditary hemochromatosis. Powell LW. Pathology 32 24-36 (2000)
  120. Hemochromatosis at the intersection of classical medicine and molecular biology. Brissot P. C R Acad Sci III 324 795-804 (2001)
  121. Interaction of the hemochromatosis gene product HFE with transferrin receptor modulates cellular iron metabolism. Eisenstein RS. Nutr Rev 56 356-358 (1998)
  122. [Advances in iron metabolism: a transition state]. Cadet E, Gadenne M, Capron D, Rochette J. Rev Med Interne 26 315-324 (2005)
  123. Advances in hepatic transport: molecular mechanisms, genetic disorders, and treatment. A summary of the 1998 AASLD single topic conference. Wolkoff AW, Suchy FJ, Moseley RH, Meier PJ, Gollan JL, Freimer N, Fitz JG, Boyer JL, Berk PD, Scharschmidt BF. Hepatology 28 1713-1719 (1998)
  124. Inherited disorders of iron storage and transport. Griffiths WJ, Kelly AL, Cox TM. Mol Med Today 5 431-438 (1999)
  125. Metabolic liver disease in the young adult. Mailliard ME, Gollan JL. Best Pract Res Clin Gastroenterol 17 307-322 (2003)
  126. Hepatology in the new millennium. Advances in viral hepatitis, hepatic disorders, and liver transplantation. Ramrakhiani S, Bacon BR. Med Clin North Am 84 1085-1105 (2000)
  127. Regulation of intracellular iron levels in iron-acceptor and iron-donor cells. Santos M, de Sousa M, Marx JJ. Transfus Sci 23 225-235 (2000)
  128. Activation of STAT and SMAD Signaling Induces Hepcidin Re-Expression as a Therapeutic Target for β-Thalassemia Patients. Saad HKM, Abd Rahman AA, Ab Ghani AS, Taib WRW, Ismail I, Johan MF, Al-Wajeeh AS, Al-Jamal HAN. Biomedicines 10 189 (2022)
  129. Cloning of the hereditary hemochromatosis gene: implications for pathogenesis, diagnosis, and screening. Himmelmann A, Fehr J. J Lab Clin Med 133 229-236 (1999)
  130. [Pathophysiology and genetics of classic HFE (type 1) hemochromatosis]. Loréal O, Ropert M, Mosser A, Déhais V, Deugnier Y, David V, Brissot P, Jouanolle AM. Presse Med 36 1271-1277 (2007)
  131. Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis. Handa S, Ginzburg Y, Hoffman R, Kremyanskaya M. Curr Opin Hematol 30 45-52 (2023)

Articles citing this publication (221)

  1. MR1 presents microbial vitamin B metabolites to MAIT cells. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, Bhati M, Chen Z, Kostenko L, Reantragoon R, Williamson NA, Purcell AW, Dudek NL, McConville MJ, O'Hair RA, Khairallah GN, Godfrey DI, Fairlie DP, Rossjohn J, McCluskey J. Nature 491 717-723 (2012)
  2. Transferrin receptor is necessary for development of erythrocytes and the nervous system. Levy JE, Jin O, Fujiwara Y, Kuo F, Andrews NC. Nat Genet 21 396-399 (1999)
  3. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Cassanelli S, Trenor CC, Gasparini P, Andrews NC, Pietrangelo A. J Clin Invest 108 619-623 (2001)
  4. Structure of the human transferrin receptor-transferrin complex. Cheng Y, Zak O, Aisen P, Harrison SC, Walz T. Cell 116 565-576 (2004)
  5. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Martin WL, West AP, Gan L, Bjorkman PJ. Mol Cell 7 867-877 (2001)
  6. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Chapman TL, Heikeman AP, Bjorkman PJ. Immunity 11 603-613 (1999)
  7. The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. Schmidt PJ, Toran PT, Giannetti AM, Bjorkman PJ, Andrews NC. Cell Metab 7 205-214 (2008)
  8. Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Li L, Fang CJ, Ryan JC, Niemi EC, Lebrón JA, Björkman PJ, Arase H, Torti FM, Torti SV, Nakamura MC, Seaman WE. Proc Natl Acad Sci U S A 107 3505-3510 (2010)
  9. Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor. Bennett MJ, Lebrón JA, Bjorkman PJ. Nature 403 46-53 (2000)
  10. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Gao J, Chen J, Kramer M, Tsukamoto H, Zhang AS, Enns CA. Cell Metab 9 217-227 (2009)
  11. Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: increased duodenal expression of the iron transporter DMT1. Fleming RE, Migas MC, Zhou X, Jiang J, Britton RS, Brunt EM, Tomatsu S, Waheed A, Bacon BR, Sly WS. Proc Natl Acad Sci U S A 96 3143-3148 (1999)
  12. Geography of HFE C282Y and H63D mutations. Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJ. Genet Test 4 183-198 (2000)
  13. Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. Moura IC, Centelles MN, Arcos-Fajardo M, Malheiros DM, Collawn JF, Cooper MD, Monteiro RC. J Exp Med 194 417-425 (2001)
  14. Congress Molecular medicine and hemochromatosis: at the crossroads. Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH. Gastroenterology 116 193-207 (1999)
  15. Genes that modify the hemochromatosis phenotype in mice. Levy JE, Montross LK, Andrews NC. J Clin Invest 105 1209-1216 (2000)
  16. Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum. Waheed A, Parkkila S, Saarnio J, Fleming RE, Zhou XY, Tomatsu S, Britton RS, Bacon BR, Sly WS. Proc Natl Acad Sci U S A 96 1579-1584 (1999)
  17. HFE mutations, iron deficiency and overload in 10,500 blood donors. Jackson HA, Carter K, Darke C, Guttridge MG, Ravine D, Hutton RD, Napier JA, Worwood M. Br J Haematol 114 474-484 (2001)
  18. Juvenile hemochromatosis locus maps to chromosome 1q. Roetto A, Totaro A, Cazzola M, Cicilano M, Bosio S, D'Ascola G, Carella M, Zelante L, Kelly AL, Cox TM, Gasparini P, Camaschella C. Am J Hum Genet 64 1388-1393 (1999)
  19. The hemochromatosis protein HFE competes with transferrin for binding to the transferrin receptor. Lebrón JA, West AP, Bjorkman PJ. J Mol Biol 294 239-245 (1999)
  20. Crystal structure of the MHC class I homolog MIC-A, a gammadelta T cell ligand. Li P, Willie ST, Bauer S, Morris DL, Spies T, Strong RK. Immunity 10 577-584 (1999)
  21. Experimental hemochromatosis due to MHC class I HFE deficiency: immune status and iron metabolism. Bahram S, Gilfillan S, Kühn LC, Moret R, Schulze JB, Lebeau A, Schümann K. Proc Natl Acad Sci U S A 96 13312-13317 (1999)
  22. Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis. Zoller H, Pietrangelo A, Vogel W, Weiss G. Lancet 353 2120-2123 (1999)
  23. The hemochromatosis proteins HFE, TfR2, and HJV form a membrane-associated protein complex for hepcidin regulation. D'Alessio F, Hentze MW, Muckenthaler MU. J Hepatol 57 1052-1060 (2012)
  24. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. Berthelot L, Papista C, Maciel TT, Biarnes-Pelicot M, Tissandie E, Wang PH, Tamouza H, Jamin A, Bex-Coudrat J, Gestin A, Boumediene A, Arcos-Fajardo M, England P, Pillebout E, Walker F, Daugas E, Vrtosvnik F, Flamant M, Benhamou M, Cogné M, Moura IC, Monteiro RC. J Exp Med 209 793-806 (2012)
  25. Transferrin receptor is negatively modulated by the hemochromatosis protein HFE: implications for cellular iron homeostasis. Salter-Cid L, Brunmark A, Li Y, Leturcq D, Peterson PA, Jackson MR, Yang Y. Proc Natl Acad Sci U S A 96 5434-5439 (1999)
  26. Transferrin receptor 1 is a reticulocyte-specific receptor for Plasmodium vivax. Gruszczyk J, Kanjee U, Chan LJ, Menant S, Malleret B, Lim NTY, Schmidt CQ, Mok YF, Lin KM, Pearson RD, Rangel G, Smith BJ, Call MJ, Weekes MP, Griffin MDW, Murphy JM, Abraham J, Sriprawat K, Menezes MJ, Ferreira MU, Russell B, Renia L, Duraisingh MT, Tham WH. Science 359 48-55 (2018)
  27. Crystal structure and ligand binding properties of the D1D2 region of the inhibitory receptor LIR-1 (ILT2). Chapman TL, Heikema AP, West AP, Bjorkman PJ. Immunity 13 727-736 (2000)
  28. Multicentric origin of hemochromatosis gene (HFE) mutations. Rochette J, Pointon JJ, Fisher CA, Perera G, Arambepola M, Arichchi DS, De Silva S, Vandwalle JL, Monti JP, Old JM, Merryweather-Clarke AT, Weatherall DJ, Robson KJ. Am J Hum Genet 64 1056-1062 (1999)
  29. Aptamer-based endocytosis of a lysosomal enzyme. Chen CH, Dellamaggiore KR, Ouellette CP, Sedano CD, Lizadjohry M, Chernis GA, Gonzales M, Baltasar FE, Fan AL, Myerowitz R, Neufeld EF. Proc Natl Acad Sci U S A 105 15908-15913 (2008)
  30. β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Josson S, Nomura T, Lin JT, Huang WC, Wu D, Zhau HE, Zayzafoon M, Weizmann MN, Gururajan M, Chung LW. Cancer Res 71 2600-2610 (2011)
  31. Crystal structure of mouse H2-M. Fremont DH, Crawford F, Marrack P, Hendrickson WA, Kappler J. Immunity 9 385-393 (1998)
  32. Mutational analysis of the transferrin receptor reveals overlapping HFE and transferrin binding sites. West AP, Giannetti AM, Herr AB, Bennett MJ, Nangiana JS, Pierce JR, Weiner LP, Snow PM, Bjorkman PJ. J Mol Biol 313 385-397 (2001)
  33. Regulation of transferrin-mediated iron uptake by HFE, the protein defective in hereditary hemochromatosis. Waheed A, Grubb JH, Zhou XY, Tomatsu S, Fleming RE, Costaldi ME, Britton RS, Bacon BR, Sly WS. Proc Natl Acad Sci U S A 99 3117-3122 (2002)
  34. Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. Pichler I, Del Greco M F, Gögele M, Lill CM, Bertram L, Do CB, Eriksson N, Foroud T, Myers RH, PD GWAS Consortium, Nalls M, Keller MF, International Parkinson's Disease Genomics Consortium, Wellcome Trust Case Control Consortium 2, Benyamin B, Whitfield JB, Genetics of Iron Status Consortium, Pramstaller PP, Hicks AA, Thompson JR, Minelli C. PLoS Med 10 e1001462 (2013)
  35. The origin and spread of the HFE-C282Y haemochromatosis mutation. Distante S, Robson KJ, Graham-Campbell J, Arnaiz-Villena A, Brissot P, Worwood M. Hum Genet 115 269-279 (2004)
  36. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. Girelli D, Bozzini C, Roetto A, Alberti F, Daraio F, Colombari R, Olivieri O, Corrocher R, Camaschella C. Gastroenterology 122 1295-1302 (2002)
  37. The hemochromatosis protein HFE inhibits iron export from macrophages. Drakesmith H, Sweetland E, Schimanski L, Edwards J, Cowley D, Ashraf M, Bastin J, Townsend AR. Proc Natl Acad Sci U S A 99 15602-15607 (2002)
  38. Crystal structures of RAE-1beta and its complex with the activating immunoreceptor NKG2D. Li P, McDermott G, Strong RK. Immunity 16 77-86 (2002)
  39. Nitric oxide inhibits H2O2-induced transferrin receptor-dependent apoptosis in endothelial cells: Role of ubiquitin-proteasome pathway. Kotamraju S, Tampo Y, Keszler A, Chitambar CR, Joseph J, Haas AL, Kalyanaraman B. Proc Natl Acad Sci U S A 100 10653-10658 (2003)
  40. The crystal structure of a TL/CD8alphaalpha complex at 2.1 A resolution: implications for modulation of T cell activation and memory. Liu Y, Xiong Y, Naidenko OV, Liu JH, Zhang R, Joachimiak A, Kronenberg M, Cheroutre H, Reinherz EL, Wang JH. Immunity 18 205-215 (2003)
  41. Are hereditary hemochromatosis mutations involved in Alzheimer disease? Moalem S, Percy ME, Andrews DF, Kruck TP, Wong S, Dalton AJ, Mehta P, Fedor B, Warren AC. Am J Med Genet 93 58-66 (2000)
  42. Kupffer cell staining by an HFE-specific monoclonal antibody: implications for hereditary haemochromatosis. Bastin JM, Jones M, O'Callaghan CA, Schimanski L, Mason DY, Townsend AR. Br J Haematol 103 931-941 (1998)
  43. HFE interacts with the BMP type I receptor ALK3 to regulate hepcidin expression. Wu XG, Wang Y, Wu Q, Cheng WH, Liu W, Zhao Y, Mayeur C, Schmidt PJ, Yu PB, Wang F, Xia Y. Blood 124 1335-1343 (2014)
  44. Hereditary hemochromatosis results in decreased iron acquisition and growth by Mycobacterium tuberculosis within human macrophages. Olakanmi O, Schlesinger LS, Britigan BE. J Leukoc Biol 81 195-204 (2007)
  45. Mechanism for multiple ligand recognition by the human transferrin receptor. Giannetti AM, Snow PM, Zak O, Björkman PJ. PLoS Biol 1 E51 (2003)
  46. Changes of gene expression of iron regulatory proteins during turpentine oil-induced acute-phase response in the rat. Sheikh N, Dudas J, Ramadori G. Lab Invest 87 713-725 (2007)
  47. The transferrin receptor binding site on HFE, the class I MHC-related protein mutated in hereditary hemochromatosis. Lebrón JA, Bjorkman PJ. J Mol Biol 289 1109-1118 (1999)
  48. Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. Moura IC, Arcos-Fajardo M, Gdoura A, Leroy V, Sadaka C, Mahlaoui N, Lepelletier Y, Vrtovsnik F, Haddad E, Benhamou M, Monteiro RC. J Am Soc Nephrol 16 2667-2676 (2005)
  49. HIV-1 Nef down-regulates the hemochromatosis protein HFE, manipulating cellular iron homeostasis. Drakesmith H, Chen N, Ledermann H, Screaton G, Townsend A, Xu XN. Proc Natl Acad Sci U S A 102 11017-11022 (2005)
  50. Evolutionary reconstructions of the transferrin receptor of Caniforms supports canine parvovirus being a re-emerged and not a novel pathogen in dogs. Kaelber JT, Demogines A, Harbison CE, Allison AB, Goodman LB, Ortega AN, Sawyer SL, Parrish CR. PLoS Pathog 8 e1002666 (2012)
  51. Intestinal expression of genes involved in iron absorption in humans. Rolfs A, Bonkovsky HL, Kohlroser JG, McNeal K, Sharma A, Berger UV, Hediger MA. Am J Physiol Gastrointest Liver Physiol 282 G598-607 (2002)
  52. Structural elucidation of the m157 mouse cytomegalovirus ligand for Ly49 natural killer cell receptors. Adams EJ, Juo ZS, Venook RT, Boulanger MJ, Arase H, Lanier LL, Garcia KC. Proc Natl Acad Sci U S A 104 10128-10133 (2007)
  53. The hereditary hemochromatosis protein, HFE, inhibits iron uptake via down-regulation of Zip14 in HepG2 cells. Gao J, Zhao N, Knutson MD, Enns CA. J Biol Chem 283 21462-21468 (2008)
  54. Hepatocyte-targeted HFE and TFR2 control hepcidin expression in mice. Gao J, Chen J, De Domenico I, Koeller DM, Harding CO, Fleming RE, Koeberl DD, Enns CA. Blood 115 3374-3381 (2010)
  55. The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy. Tamouza H, Chemouny JM, Raskova Kafkova L, Berthelot L, Flamant M, Demion M, Mesnard L, Paubelle E, Walker F, Julian BA, Tissandié E, Tiwari MK, Camara NO, Vrtovsnik F, Benhamou M, Novak J, Monteiro RC, Moura IC. Kidney Int 82 1284-1296 (2012)
  56. Stimulation of an unfolded protein response impairs MHC class I expression. de Almeida SF, Fleming JV, Azevedo JE, Carmo-Fonseca M, de Sousa M. J Immunol 178 3612-3619 (2007)
  57. Bibliography Survey of the 1998 optical biosensor literature. Myszka DG. J Mol Recognit 12 390-408 (1999)
  58. Contribution of the H63D mutation in HFE to murine hereditary hemochromatosis. Tomatsu S, Orii KO, Fleming RE, Holden CC, Waheed A, Britton RS, Gutierrez MA, Velez-Castrillon S, Bacon BR, Sly WS. Proc Natl Acad Sci U S A 100 15788-15793 (2003)
  59. Uncommon mutations and polymorphisms in the hemochromatosis gene. Pointon JJ, Wallace D, Merryweather-Clarke AT, Robson KJ. Genet Test 4 151-161 (2000)
  60. Interacting signals in the control of hepcidin expression. Darshan D, Anderson GJ. Biometals 22 77-87 (2009)
  61. Amyloidogenic regions and interaction surfaces overlap in globular proteins related to conformational diseases. Castillo V, Ventura S. PLoS Comput Biol 5 e1000476 (2009)
  62. Role of HFE in iron metabolism, hereditary haemochromatosis, anaemia of chronic disease, and secondary iron overload. Townsend A, Drakesmith H. Lancet 359 786-790 (2002)
  63. Human cytomegalovirus protein US2 interferes with the expression of human HFE, a nonclassical class I major histocompatibility complex molecule that regulates iron homeostasis. Ben-Arieh SV, Zimerman B, Smorodinsky NI, Yaacubovicz M, Schechter C, Bacik I, Gibbs J, Bennink JR, Yewdell JW, Coligan JE, Firat H, Lemonnier F, Ehrlich R. J Virol 75 10557-10562 (2001)
  64. Linkage disequilibrium analysis in Australian haemochromatosis patients indicates bipartite association with clinical expression. Pratiwi R, Fletcher LM, Pyper WR, Do KA, Crawford DH, Powell LW, Jazwinska EC. J Hepatol 31 39-46 (1999)
  65. Iron overload in adult Hfe-deficient mice independent of changes in the steady-state expression of the duodenal iron transporters DMT1 and Ireg1/ferroportin. Herrmann T, Muckenthaler M, van der Hoeven F, Brennan K, Gehrke SG, Hubert N, Sergi C, Gröne HJ, Kaiser I, Gosch I, Volkmann M, Riedel HD, Hentze MW, Stewart AF, Stremmel W. J Mol Med (Berl) 82 39-48 (2004)
  66. Overexpression of the hereditary hemochromatosis protein, HFE, in HeLa cells induces and iron-deficient phenotype. Corsi B, Levi S, Cozzi A, Corti A, Altimare D, Albertini A, Arosio P. FEBS Lett 460 149-152 (1999)
  67. Polymeric IgA1 controls erythroblast proliferation and accelerates erythropoiesis recovery in anemia. Coulon S, Dussiot M, Grapton D, Maciel TT, Wang PH, Callens C, Tiwari MK, Agarwal S, Fricot A, Vandekerckhove J, Tamouza H, Zermati Y, Ribeil JA, Djedaini K, Oruc Z, Pascal V, Courtois G, Arnulf B, Alyanakian MA, Mayeux P, Leanderson T, Benhamou M, Cogné M, Monteiro RC, Hermine O, Moura IC. Nat Med 17 1456-1465 (2011)
  68. Effect of transfusional iron overload on immune response. Cunningham-Rundles S, Giardina PJ, Grady RW, Califano C, McKenzie P, De Sousa M. J Infect Dis 182 Suppl 1 S115-21 (2000)
  69. Purified feline and canine transferrin receptors reveal complex interactions with the capsids of canine and feline parvoviruses that correspond to their host ranges. Palermo LM, Hafenstein SL, Parrish CR. J Virol 80 8482-8492 (2006)
  70. Direct recognition by alphabeta cytolytic T cells of Hfe, a MHC class Ib molecule without antigen-presenting function. Rohrlich PS, Fazilleau N, Ginhoux F, Firat H, Michel F, Cochet M, Laham N, Roth MP, Pascolo S, Nato F, Coppin H, Charneau P, Danos O, Acuto O, Ehrlich R, Kanellopoulos J, Lemonnier FA. Proc Natl Acad Sci U S A 102 12855-12860 (2005)
  71. Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction. Papista C, Lechner S, Ben Mkaddem S, LeStang MB, Abbad L, Bex-Coudrat J, Pillebout E, Chemouny JM, Jablonski M, Flamant M, Daugas E, Vrtovsnik F, Yiangou M, Berthelot L, Monteiro RC. Kidney Int 88 276-285 (2015)
  72. Reciprocal regulation of HFE and NNamp2 gene expression by iron in human intestinal cells. Han O, Fleet JC, Wood RJ. J Nutr 129 98-104 (1999)
  73. Cryo-EM structure of the human ferritin-transferrin receptor 1 complex. Montemiglio LC, Testi C, Ceci P, Falvo E, Pitea M, Savino C, Arcovito A, Peruzzi G, Baiocco P, Mancia F, Boffi A, des Georges A, Vallone B. Nat Commun 10 1121 (2019)
  74. Differing impact of the deletion of hemochromatosis-associated molecules HFE and transferrin receptor-2 on the iron phenotype of mice lacking bone morphogenetic protein 6 or hemojuvelin. Latour C, Besson-Fournier C, Meynard D, Silvestri L, Gourbeyre O, Aguilar-Martinez P, Schmidt PJ, Fleming MD, Roth MP, Coppin H. Hepatology 63 126-137 (2016)
  75. High prevalence of the hemochromatosis-associated Cys282Tyr HFE gene mutation in a healthy Norwegian population in the city of Oslo, and its phenotypic expression. Distante S, Berg JP, Lande K, Haug E, Bell H. Scand J Gastroenterol 34 529-534 (1999)
  76. Soluble transferrin receptor as a potential determinant of iron loading in congenital anaemias due to ineffective erythropoiesis. Cazzola M, Beguin Y, Bergamaschi G, Guarnone R, Cerani P, Barella S, Cao A, Galanello R. Br J Haematol 106 752-755 (1999)
  77. Regulatory networks for the control of body iron homeostasis and their dysregulation in HFE mediated hemochromatosis. Ludwiczek S, Theurl I, Bahram S, Schümann K, Weiss G. J Cell Physiol 204 489-499 (2005)
  78. Duodenal HFE expression and hepcidin levels determine body iron homeostasis: modulation by genetic diversity and dietary iron availability. Ludwiczek S, Theurl I, Artner-Dworzak E, Chorney M, Weiss G. J Mol Med (Berl) 82 373-382 (2004)
  79. Enhanced erythropoiesis in Hfe-KO mice indicates a role for Hfe in the modulation of erythroid iron homeostasis. Ramos P, Guy E, Chen N, Proenca CC, Gardenghi S, Casu C, Follenzi A, Van Rooijen N, Grady RW, de Sousa M, Rivella S. Blood 117 1379-1389 (2011)
  80. Gamma delta intraepithelial lymphocytes drive tumor necrosis factor-alpha responsiveness to intestinal iron challenge: relevance to hemochromatosis. Ten Elshof AE, Brittenham GM, Chorney KA, Page MJ, Gerhard G, Cable EE, Chorney MJ. Immunol Rev 167 223-232 (1999)
  81. Structure of a pheromone receptor-associated MHC molecule with an open and empty groove. Olson R, Huey-Tubman KE, Dulac C, Bjorkman PJ. PLoS Biol 3 e257 (2005)
  82. Transferrin Receptors TfR1 and TfR2 Bind Transferrin through Differing Mechanisms. Kleven MD, Jue S, Enns CA. Biochemistry 57 1552-1559 (2018)
  83. An iron-dependent and transferrin-mediated cellular uptake pathway for plutonium. Jensen MP, Gorman-Lewis D, Aryal B, Paunesku T, Vogt S, Rickert PG, Seifert S, Lai B, Woloschak GE, Soderholm L. Nat Chem Biol 7 560-565 (2011)
  84. Co-localization of the mammalian hemochromatosis gene product (HFE) and a newly identified transferrin receptor (TfR2) in intestinal tissue and cells. Griffiths WJ, Cox TM. J Histochem Cytochem 51 613-624 (2003)
  85. Frequency of the S65C mutation of HFE and iron overload in 309 subjects heterozygous for C282Y. Wallace DF, Walker AP, Pietrangelo A, Clare M, Bomford AB, Dixon JL, Powell LW, Subramaniam VN, Dooley JS. J Hepatol 36 474-479 (2002)
  86. HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of haemochromatosis. Distante S, Berg JP, Lande K, Haug E, Bell H. Gut 47 575-579 (2000)
  87. Noncanonical interactions between serum transferrin and transferrin receptor evaluated with electrospray ionization mass spectrometry. Leverence R, Mason AB, Kaltashov IA. Proc Natl Acad Sci U S A 107 8123-8128 (2010)
  88. A conserved RGD (Arg-Gly-Asp) motif in the transferrin receptor is required for binding to transferrin. Dubljevic V, Sali A, Goding JW. Biochem J 341 ( Pt 1) 11-14 (1999)
  89. Research Support, Non-U.S. Gov't Function of the hemochromatosis protein HFE: Lessons from animal models. Pantopoulos K. World J Gastroenterol 14 6893-6901 (2008)
  90. Overexpression of hemochromatosis protein, HFE, alters transferrin recycling process in human hepatoma cells. Ikuta K, Fujimoto Y, Suzuki Y, Tanaka K, Saito H, Ohhira M, Sasaki K, Kohgo Y. Biochim Biophys Acta 1496 221-231 (2000)
  91. Binding to the transferrin receptor is required for endocytosis of HFE and regulation of iron homeostasis. Ramalingam TS, West AP, Lebrón JA, Nangiana JS, Hogan TH, Enns CA, Bjorkman PJ. Nat Cell Biol 2 953-957 (2000)
  92. Crosstalk between Iron Metabolism and Erythropoiesis. Li H, Ginzburg YZ. Adv Hematol 2010 605435 (2010)
  93. Direct peptide-regulatable interactions between MHC class I molecules and tapasin. Rizvi SM, Raghavan M. Proc Natl Acad Sci U S A 103 18220-18225 (2006)
  94. Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins. Yoon DJ, Chu DS, Ng CW, Pham EA, Mason AB, Hudson DM, Smith VC, MacGillivray RT, Kamei DT. J Control Release 133 178-184 (2009)
  95. In situ proximity ligation assays indicate that hemochromatosis proteins Hfe and transferrin receptor 2 (Tfr2) do not interact. Rishi G, Crampton EM, Wallace DF, Subramaniam VN. PLoS One 8 e77267 (2013)
  96. Iron overload in HFE C282Y heterozygotes at first genetic testing: a strategy for identifying rare HFE variants. Aguilar-Martinez P, Grandchamp B, Cunat S, Cadet E, Blanc F, Nourrit M, Lassoued K, Schved JF, Rochette J. Haematologica 96 507-514 (2011)
  97. Cryo-EM structure of an essential Plasmodium vivax invasion complex. Gruszczyk J, Huang RK, Chan LJ, Menant S, Hong C, Murphy JM, Mok YF, Griffin MDW, Pearson RD, Wong W, Cowman AF, Yu Z, Tham WH. Nature 559 135-139 (2018)
  98. Huh-7: a human "hemochromatotic" cell line. Vecchi C, Montosi G, Pietrangelo A. Hepatology 51 654-659 (2010)
  99. A WHO reference reagent for the Serum Transferrin Receptor (sTfR): international collaborative study to evaluate a recombinant soluble transferrin receptor preparation. Thorpe SJ, Heath A, Sharp G, Cook J, Ellis R, Worwood M. Clin Chem Lab Med 48 815-820 (2010)
  100. A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity. Klein JS, Webster A, Gnanapragasam PN, Galimidi RP, Bjorkman PJ. AIDS 24 1633-1640 (2010)
  101. Increased IRP1 and IRP2 RNA binding activity accompanies a reduction of the labile iron pool in HFE-expressing cells. Roy CN, Blemings KP, Deck KM, Davies PS, Anderson EL, Eisenstein RS, Enns CA. J Cell Physiol 190 218-226 (2002)
  102. Localization of iron transport and regulatory proteins in human cells. Griffiths WJ, Kelly AL, Smith SJ, Cox TM. QJM 93 575-587 (2000)
  103. Structural and functional mosaic nature of MHC class I molecules in their peptide-free form. Kurimoto E, Kuroki K, Yamaguchi Y, Yagi-Utsumi M, Igaki T, Iguchi T, Maenaka K, Kato K. Mol Immunol 55 393-399 (2013)
  104. The effect of transferrin polymorphisms on iron metabolism. Lee PL, Ho NJ, Olson R, Beutler E. Blood Cells Mol Dis 25 374-379 (1999)
  105. Differential HFE allele expression in hemochromatosis heterozygotes. Rosmorduc O, Poupon R, Nion I, Wendum D, Feder J, Béréziat G, Hermelin B. Gastroenterology 119 1075-1086 (2000)
  106. Gene expression of divalent metal transporter 1 and transferrin receptor in duodenum of Belgrade rats. Oates PS, Thomas C, Freitas E, Callow MJ, Morgan EH. Am J Physiol Gastrointest Liver Physiol 278 G930-6 (2000)
  107. Infection with Mycobacterium avium differentially regulates the expression of iron transport protein mRNA in murine peritoneal macrophages. Zhong W, Lafuse WP, Zwilling BS. Infect Immun 69 6618-6624 (2001)
  108. Non-classical hereditary hemochromatosis in Portugal: novel mutations identified in iron metabolism-related genes. Mendes AI, Ferro A, Martins R, Picanço I, Gomes S, Cerqueira R, Correia M, Nunes AR, Esteves J, Fleming R, Faustino P. Ann Hematol 88 229-234 (2009)
  109. Purification and characterization of zinc alpha2-glycoprotein-prolactin inducible protein complex from human seminal plasma. Hassan MI, Kumar V, Singh TP, Yadav S. J Sep Sci 31 2318-2324 (2008)
  110. Real-time polymerase chain reaction with fluorescent hybridization probes for the detection of prevalent mutations causing common thrombophilic and iron overload phenotypes. Parks SB, Popovich BW, Press RD. Am J Clin Pathol 115 439-447 (2001)
  111. A loop in the N-lobe of human serum transferrin is critical for binding to the transferrin receptor as revealed by mutagenesis, isothermal titration calorimetry, and epitope mapping. Mason AB, Byrne SL, Everse SJ, Roberts SE, Chasteen ND, Smith VC, MacGillivray RT, Kandemir B, Bou-Abdallah F. J Mol Recognit 22 521-529 (2009)
  112. Evidence for the interaction of the hereditary haemochromatosis protein, HFE, with the transferrin receptor in endocytic compartments. Davies PS, Zhang AS, Anderson EL, Roy CN, Lampson MA, McGraw TE, Enns CA. Biochem J 373 145-153 (2003)
  113. Parvovirus infection of cells by using variants of the feline transferrin receptor altering clathrin-mediated endocytosis, membrane domain localization, and capsid-binding domains. Hueffer K, Palermo LM, Parrish CR. J Virol 78 5601-5611 (2004)
  114. The extracellular regions of PSMA and the transferrin receptor contain an aminopeptidase domain: implications for drug design. Mahadevan D, Saldanha JW. Protein Sci 8 2546-2549 (1999)
  115. Transferrin receptor co-localizes and interacts with the hemochromatosis factor (HFE) and the divalent metal transporter-1 (DMT1) in trophoblast cells. Gruper Y, Bar J, Bacharach E, Ehrlich R. J Cell Physiol 204 901-912 (2005)
  116. Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy. Amreddy N, Muralidharan R, Babu A, Mehta M, Johnson EV, Zhao YD, Munshi A, Ramesh R. Int J Nanomedicine 10 6773-6788 (2015)
  117. Crystal structure of TNFalpha complexed with a poxvirus MHC-related TNF binding protein. Yang Z, West AP, Bjorkman PJ. Nat Struct Mol Biol 16 1189-1191 (2009)
  118. Conservation of sequence motifs suggests that the nonclassical MHC class I lineages CD1/PROCR and UT were established before the emergence of tetrapod species. Dijkstra JM, Yamaguchi T, Grimholt U. Immunogenetics 70 459-476 (2018)
  119. Genetic and Dietary Iron Overload Differentially Affect the Course of Salmonella Typhimurium Infection. Nairz M, Schroll A, Haschka D, Dichtl S, Tymoszuk P, Demetz E, Moser P, Haas H, Fang FC, Theurl I, Weiss G. Front Cell Infect Microbiol 7 110 (2017)
  120. Inhibition of transferrin iron release increases in vitro drug carrier efficacy. Lao BJ, Tsai WL, Mashayekhi F, Pham EA, Mason AB, Kamei DT. J Control Release 117 403-412 (2007)
  121. Interactions of the ectodomain of HFE with the transferrin receptor are critical for iron homeostasis in cells. Roy CN, Carlson EJ, Anderson EL, Basava A, Starnes SM, Feder JN, Enns CA. FEBS Lett 484 271-274 (2000)
  122. Iron transport kinetics through blood-brain barrier endothelial cells. Khan AI, Liu J, Dutta P. Biochim Biophys Acta Gen Subj 1862 1168-1179 (2018)
  123. Phlebotomy increases cadmium uptake in hemochromatosis. Akesson A, Stål P, Vahter M. Environ Health Perspect 108 289-291 (2000)
  124. T-cell receptor repertoire in hereditary hemochromatosis: a study of 32 hemochromatosis patients and 274 healthy subjects. Cardoso C, Porto G, Lacerda R, Resende D, Rodrigues P, Bravo F, Oliveira JC, Justiça B, de Sousa M. Hum Immunol 62 488-499 (2001)
  125. The haemochromatosis protein HFE induces an apparent iron-deficient phenotype in H1299 cells that is not corrected by co-expression of beta 2-microglobulin. Wang J, Chen G, Pantopoulos K. Biochem J 370 891-899 (2003)
  126. Transferrin-iron routing to the cytosol and mitochondria as studied by live and real-time fluorescence. Shvartsman M, Fibach E, Cabantchik ZI. Biochem J 429 185-193 (2010)
  127. A hemochromatosis-causing mutation C282Y is a risk factor for proliferative diabetic retinopathy in Caucasians with type 2 diabetes. Peterlin B, Globočnik Petrovič M, Makuc J, Hawlina M, Petrovič D. J Hum Genet 48 646-649 (2003)
  128. Mechanisms of HFE-induced regulation of iron homeostasis: Insights from the W81A HFE mutation. Zhang AS, Davies PS, Carlson HL, Enns CA. Proc Natl Acad Sci U S A 100 9500-9505 (2003)
  129. Phenotypic expression of the C282Y/Q283P compound heterozygosity in HFE and molecular modeling of the Q283P mutation effect. Le Gac G, Dupradeau FY, Mura C, Jacolot S, Scotet V, Esnault G, Mercier AY, Rochette J, Férec C. Blood Cells Mol Dis 30 231-237 (2003)
  130. The effects of wild-type and mutant HFE expression upon cellular iron uptake in transfected human embryonic kidney cells. Feeney GP, Worwood M. Biochim Biophys Acta 1538 242-251 (2001)
  131. Low penetrant hemochromatosis phenotype in eight families: no evidence of modifiers in the MHC region. Sachot S, Moirand R, Jouanolle AM, Mosser J, Fergelot P, Deugnier Y, Brissot P, le Gall JY, David V. Blood Cells Mol Dis 27 518-529 (2001)
  132. Molecular basis of the structural stability of hemochromatosis factor E: A combined molecular dynamic simulation and GdmCl-induced denaturation study. Khan P, Parkash A, Islam A, Ahmad F, Hassan MI. Biopolymers 105 133-142 (2016)
  133. Changes in major proteins in the embryonic capsule during immobilization (fixation) of the conceptus in the third week of pregnancy in the mare. Quinn BA, Hayes MA, Waelchli RO, Kennedy MW, Betteridge KJ. Reproduction 134 161-170 (2007)
  134. Conserved lipid and peptide presentation functions of nonclassical class I molecules. Kronenberg M, Brossay L, Kurepa Z, Forman J. Immunol Today 20 515-521 (1999)
  135. ER Stress and Iron Homeostasis: A New Frontier for the UPR. Oliveira SJ, de Sousa M, Pinto JP. Biochem Res Int 2011 896474 (2011)
  136. HFE association with transferrin receptor 2 increases cellular uptake of transferrin-bound iron. Waheed A, Britton RS, Grubb JH, Sly WS, Fleming RE. Arch Biochem Biophys 474 193-197 (2008)
  137. HJV and HFE Play Distinct Roles in Regulating Hepcidin. Wu Q, Wang H, An P, Tao Y, Deng J, Zhang Z, Shen Y, Chen C, Min J, Wang F. Antioxid Redox Signal 22 1325-1336 (2015)
  138. Stoichiometries of transferrin receptors 1 and 2 in human liver. Chloupková M, Zhang AS, Enns CA. Blood Cells Mol Dis 44 28-33 (2010)
  139. The WT hemochromatosis protein HFE inhibits CD8⁺ T-lymphocyte activation. Reuben A, Phénix M, Santos MM, Lapointe R. Eur J Immunol 44 1604-1614 (2014)
  140. Ubiquitination of lysine-331 by Kaposi's sarcoma-associated herpesvirus protein K5 targets HFE for lysosomal degradation. Rhodes DA, Boyle LH, Boname JM, Lehner PJ, Trowsdale J. Proc Natl Acad Sci U S A 107 16240-16245 (2010)
  141. A role for the MHC class I-like Mill molecules in nutrient metabolism and wound healing. Rabinovich BA, Ketchem RR, Wolfson M, Goldstein L, Skelly M, Cosman D. Immunol Cell Biol 86 489-496 (2008)
  142. The hHFE gene of browsing and grazing rhinoceroses: a possible site of adaptation to a low-iron diet. Beutler E, West C, Speir JA, Wilson IA, Worley M. Blood Cells Mol Dis 27 342-350 (2001)
  143. Binding of Chromium(III) to Transferrin Could Be Involved in Detoxification of Dietary Chromium(III) Rather than Transport of an Essential Trace Element. Levina A, Pham TH, Lay PA. Angew Chem Int Ed Engl 55 8104-8107 (2016)
  144. Complete characterization of the 3' region of the human and mouse hereditary hemochromatosis HFE gene and detection of novel splicing forms. Sánchez M, Bruguera M, Rodés J, Oliva R. Blood Cells Mol Dis 27 35-43 (2001)
  145. HFE mutations and transferrin receptor polymorphism analysis in porphyria cutanea tarda: a prospective study of 36 cases from southern France. Dereure O, Aguilar-Martinez P, Bessis D, Perney P, Vallat C, Guillot B, Blanc F, Guilhou JJ. Br J Dermatol 144 533-539 (2001)
  146. Molecular biology and the diagnosis and treatment of liver diseases. Worman HJ, Feng L, Mamiya N. World J Gastroenterol 4 185-191 (1998)
  147. Multivalent metal-induced iron acquisition from transferrin and lactoferrin by myeloid cells. Olakanmi O, Rasmussen GT, Lewis TS, Stokes JB, Kemp JD, Britigan BE. J Immunol 169 2076-2084 (2002)
  148. A TfR-Binding Cystine-Dense Peptide Promotes Blood-Brain Barrier Penetration of Bioactive Molecules. Crook ZR, Girard E, Sevilla GP, Merrill M, Friend D, Rupert PB, Pakiam F, Nguyen E, Yin C, Ruff RO, Hopping G, Strand AD, Finton KAK, Coxon M, Mhyre AJ, Strong RK, Olson JM. J Mol Biol 432 3989-4009 (2020)
  149. Commentary on HFE S65C variant is not associated with increased transferrin saturation in voluntary blood donors by Naveen Arya, Subrata Chakrabrati, Robert A. Hegele, Paul C. Adams. Beutler E, Felitti VJ, Ho NJ, Gelbart T. Blood Cells Mol Dis 25 358-360 (1999)
  150. Iron overload in mice expressing HFE exclusively in the intestinal villi provides evidence that HFE regulates a functional cross-talk between crypt and villi enterocytes. Fergelot P, Ropert-Bouchet M, Abgueguen E, Orhant M, Radosavljevic M, Grimber G, Jouan H, Le Gall JY, Mosser J, Gilfillan S, Bahram S. Blood Cells Mol Dis 28 348-360 (2002)
  151. Monocyte-macrophage ferric reductase activity is inhibited by iron and stimulated by cellular differentiation. Partridge J, Wallace DF, Raja KB, Dooley JS, Walker AP. Biochem J 336 ( Pt 3) 541-543 (1998)
  152. Regulatory effects of tumor necrosis factor-alpha and interleukin-6 on HAMP expression in iron loaded rat hepatocytes. Dzikaite V, Holmström P, Stål P, Eckes K, Hagen K, Eggertsen G, Gåfvels M, Melefors O, Hultcrantz R. J Hepatol 44 544-551 (2006)
  153. The discovery of the new haemochromatosis gene. 1996. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A. J Hepatol 38 704-709 (2003)
  154. Tolerization of adult mice to immunodominant proteins before monoclonal antibody production. Lebrón JA, Shen H, Bjorkman PJ, Ou S. J Immunol Methods 222 59-63 (1999)
  155. Hemochromatosis protein (HFE) and tumor necrosis factor receptor 2 (TNFR2) influence tissue iron levels: elements of a common gut pathway? Meyer PN, Gerhard GS, Yoshida Y, Yoshida M, Chorney KA, Beard J, Kauffman EJ, Weiss G, Chorney MJ. Blood Cells Mol Dis 29 274-285 (2002)
  156. Protective role of calreticulin in HFE hemochromatosis. Pinto JP, Ramos P, de Almeida SF, Oliveira S, Breda L, Michalak M, Porto G, Rivella S, de Sousa M. Free Radic Biol Med 44 99-108 (2008)
  157. The HFE gene undergoes alternate splicing processes. Thénié A, Orhant M, Gicquel I, Fergelot P, Le Gall JY, David V, Mosser J. Blood Cells Mol Dis 26 155-162 (2000)
  158. A compartmental model of iron regulation in the mouse. Lao BJ, Kamei DT. J Theor Biol 243 542-554 (2006)
  159. A very rare association of three mutations of the HFE gene for hemochromatosis. Menardi G, Perotti L, Prucca M, Martini S, Prandi G, Peano G. Genet Test 6 331-334 (2002)
  160. Characterization of the interaction between diferric transferrin and transferrin receptor 2 by functional assays and atomic force microscopy. Ikuta K, Yersin A, Ikai A, Aisen P, Kohgo Y. J Mol Biol 397 375-384 (2010)
  161. Iron-independent specific protein expression pattern in the liver of HFE-deficient mice. Petrak J, Myslivcova D, Halada P, Cmejla R, Cmejlova J, Vyoral D, Vulpe CD. Int J Biochem Cell Biol 39 1006-1015 (2007)
  162. Multiplex analysis of the most common mutations related to hereditary haemochromatosis: two methods combining specific amplification with capillary electrophoresis. Gómez-Llorente C, Antúnez A, Blanco S, Suarez A, Gómez-Capilla JA, Farez-Vidal ME. Eur J Haematol 72 121-129 (2004)
  163. Neither human hephaestin nor ceruloplasmin forms a stable complex with transferrin. Hudson DM, Krisinger MJ, Griffiths TA, Macgillivray RT. J Cell Biochem 103 1849-1855 (2008)
  164. Rare HFE variants are the most frequent cause of hemochromatosis in non-c282y homozygous patients with hemochromatosis. Hamdi-Rozé H, Beaumont-Epinette MP, Ben Ali Z, Le Lan C, Loustaud-Ratti V, Causse X, Loreal O, Deugnier Y, Brissot P, Jouanolle AM, Bardou-Jacquet E. Am J Hematol 91 1202-1205 (2016)
  165. The Q283P amino-acid change in HFE leads to structural and functional consequences similar to those described for the mutated 282Y HFE protein. Ka C, Le Gac G, Dupradeau FY, Rochette J, Férec C. Hum Genet 117 467-475 (2005)
  166. Effect of iron status on DMT1 expression in duodenal enterocytes from beta2-microglobulin knockout mice. Moos T, Trinder D, Morgan EH. Am J Physiol Gastrointest Liver Physiol 283 G687-94 (2002)
  167. Identification of hemochromatosis gene polymorphisms in chronically transfused patients with sickle cell disease. Jeng MR, Adams-Graves P, Howard TA, Whorton MR, Li CS, Ware RE. Am J Hematol 74 243-248 (2003)
  168. Identification of the epitope of a monoclonal antibody that disrupts binding of human transferrin to the human transferrin receptor. Teh EM, Hewitt J, Ung KC, Griffiths TA, Nguyen V, Briggs SK, Mason AB, MacGillivray RT. FEBS J 272 6344-6353 (2005)
  169. Iron metabolism in macrophages from HFE hemochromatosis patients. Jacolot S, Yang Y, Paitry P, Férec C, Mura C. Mol Genet Metab 101 258-267 (2010)
  170. The role of hereditary hemochromatosis in aseptic loosening following primary total hip arthroplasty. Lunn JV, Gallagher PM, Hegarty S, Kaliszer M, Crowe J, Murray P, Bouchier-Hayes D. J Orthop Res 23 542-548 (2005)
  171. β2-microglobulin induces epithelial-mesenchymal transition in human renal proximal tubule epithelial cells in vitro. Zhang A, Wang B, Yang M, Shi H, Gan W. BMC Nephrol 16 60 (2015)
  172. HFE Genotype Restricts the Response to Paraquat in a Mouse Model of Neurotoxicity. Nixon AM, Meadowcroft MD, Neely EB, Snyder AM, Purnell CJ, Wright J, Lamendella R, Nandar W, Huang X, Connor JR. J Neurochem 145 299-311 (2018)
  173. In vitro binding of HFE to the cation-independent mannose-6 phosphate receptor. Schimanski LM, Drakesmith H, Sweetland E, Bastin J, Rezgui D, Edelmann M, Kessler B, Merryweather-Clarke AT, Robson KJ, Townsend AR. Blood Cells Mol Dis 43 180-193 (2009)
  174. Iron-overload and genotypic expression of HFE mutations H63D/C282Y and transferrin receptor Hin6I and BanI polymorphism in german patients with hereditary haemochromatosis. Gottschalk R, Seidl C, Schilling S, Braner A, Seifried E, Hoelzer D, Kaltwasser JP. Eur J Immunogenet 27 129-134 (2000)
  175. Loss of central and peripheral CD8+ T-cell tolerance to HFE in mouse models of human familial hemochromatosis. Boucherma R, Kridane-Miledi H, Vives FL, Vauchy C, Borg C, Kleinclauss F, Fiette L, Tiberghien P, Lemonnier FA, Rohrlich PS, Huetz F. Eur J Immunol 42 851-862 (2012)
  176. N-glycosylation is important for the correct intracellular localization of HFE and its ability to decrease cell surface transferrin binding. Bhatt L, Murphy C, O'Driscoll LS, Carmo-Fonseca M, McCaffrey MW, Fleming JV. FEBS J 277 3219-3234 (2010)
  177. Qa-1-Restricted CD8+ T Cells Can Compensate for the Absence of Conventional T Cells during Viral Infection. Anderson CK, Reilly EC, Lee AY, Brossay L. Cell Rep 27 537-548.e5 (2019)
  178. Structural basis of urea-induced unfolding: Unraveling the folding pathway of hemochromatosis factor E. Khan P, Prakash A, Haque MA, Islam A, Hassan MI, Ahmad F. Int J Biol Macromol 91 1051-1061 (2016)
  179. The Correlation of Cardiac and Hepatic Hemosiderosis as Measured by T2*MRI Technique with Ferritin Levels and Hemochromatosis Gene Mutations in Iranian Patients with Beta Thalassemia Major. Soltanpour MS, Davari K. Oman Med J 33 48-54 (2018)
  180. The ethnospecific distribution of the HFE haplotypes for IVS2(+4)t/c, IVS4(-44)t/c, and IVS5(-47)g/a in populations of Russia and possible effects of these single-nucleotide polymorphisms in splicing. Mikhailova SV, Babenko VN, Voevoda MI, Romashchenko AG. Genet Test Mol Biomarkers 14 461-469 (2010)
  181. Transferrin [corrected] receptor association and endosomal localization of soluble HFE are not sufficient for regulation of cellular iron homeostasis. Laham N, Rotem-Yehudar R, Shechter C, Coligan JE, Ehrlich R. J Cell Biochem 91 1130-1145 (2004)
  182. Variation in the HFE gene is associated with the development of bleomycin-induced pulmonary toxicity in testicular cancer patients. van der Schoot GGF, Westerink NL, Lubberts S, Nuver J, Zwart N, Walenkamp AME, Wempe JB, Meijer C, Gietema JA. Eur J Cancer 59 134-141 (2016)
  183. A novel (Leu183Pro-)mutation in the HFE-gene co-inherited with the Cys282Tyr mutation in two unrelated Dutch hemochromatosis patients. Swinkels DW, Venselaar H, Wiegerinck ET, Bakker E, Joosten I, Jaspers CA, Vasmel WL, Breuning MH. Blood Cells Mol Dis 40 334-338 (2008)
  184. Comparison of soluble and placental transferrin receptors as standards for the determination of soluble transferrin receptor in humans. Kogan AE, Filatov VL, Kara AN, Levina AA, Katrukha AG. Int J Lab Hematol 29 335-340 (2007)
  185. HFE gene mutation and iron overload in Egyptian pediatric acute lymphoblastic leukemia survivors: a single-center study. El-Rashedi FH, El-Hawy MA, El-Hefnawy SM, Mohammed MM. Hematology 22 398-404 (2017)
  186. High prevalence of non-HFE gene-associated haemochromatosis in patients from southern Italy. De Marco F, Liguori R, Giardina MG, D'Armiento M, Angelucci E, Lucariello A, Morante R, Cimino L, Galeota-Lanza A, Tarantino G, Ascione A, Budillon G, Vecchione R, Martinelli R, Matarazzo M, De Simone V. Clin Chem Lab Med 42 17-24 (2004)
  187. T lymphocyte-derived TNF and IFN-γ repress HFE expression in cancer cells. Reuben A, Godin-Ethier J, Santos MM, Lapointe R. Mol Immunol 65 259-266 (2015)
  188. The role of HFE genotype in macrophage phenotype. Nixon AM, Neely E, Simpson IA, Connor JR. J Neuroinflammation 15 30 (2018)
  189. A 3-dimensional model building by homology of the HFE protein: molecular consequences and application to antibody development. Dupradeau F, Altenberg-Greulich B, Warin R, Fuentes V, Monti J, Rochette J. Biochim Biophys Acta 1481 213-221 (2000)
  190. A 6-year survey of HFE gene test for hemochromatosis diagnosis. Mura C, Raguénes O, Scotet V, Jacolot S, Mercier AY, Férec C. Genet Med 7 68-73 (2005)
  191. Controversial Role of Transferrin in the Transport of Ruthenium Anticancer Drugs. Levina A, Chetcuti ARM, Lay PA. Biomolecules 12 1319 (2022)
  192. Effect of pH on the stability of hemochromatosis factor E: a combined spectroscopic and molecular dynamics simulation-based study. Khan P, Shandilya A, Jayaram B, Islam A, Ahmad F, Hassan MI. J Biomol Struct Dyn 35 1582-1598 (2017)
  193. Naturally acquired blocking human monoclonal antibodies to Plasmodium vivax reticulocyte binding protein 2b. Chan LJ, Gandhirajan A, Carias LL, Dietrich MH, Vadas O, Visentin R, França CT, Menant S, Soldati-Favre D, Mueller I, King CL, Tham WH. Nat Commun 12 1538 (2021)
  194. Novel MHC class I-related molecule MR1 affects MHC class I expression in 293T cells. Aldemir H. Biochem Biophys Res Commun 366 328-334 (2008)
  195. Unique frequencies of HFE gene variants in Roma/Gypsies. Gabriková D, Bernasovská J, Mačeková S, Bôžiková A, Bernasovský I, Bališinová A, Sovičová A, Behulová R, Petrejčíková E, Soták M, Boroňová I. J Appl Genet 53 183-187 (2012)
  196. Letter Are His63Asp or Cys282Tyr HFE mutations associated with porphyria cutanea tarda? Data of patients from central and southern Italy. D'Amato M, Macrí A, Griso D, Biolcati G, Ameglio F. J Invest Dermatol 111 1241-1242 (1998)
  197. Case Reports Hereditary haemochromatosis, haemophagocytic lymphohistiocytosis and COVID-19. Riley MJ, Hicks SR, Irvine S, Blanchard TJ, Britton E, Shawki H, Sajid Pervaiz M, Fletcher TE. Clin Infect Pract 7 100052 (2020)
  198. Immunological study of complex formation between soluble transferrin receptor and transferrin. Kogan A, Filatov V, Gusev N, Bereznikova A, Kolosova O, Katrukha A. Am J Hematol 79 281-287 (2005)
  199. Manifestation of rheumatoid arthritis in a patient with hereditary haemochromatosis. Wernicke D, Seipelt E, Schmidt WA, Gromnica-Ihle E. Rheumatol Int 26 939-941 (2006)
  200. Phenotypic expression of a novel C282Y/R226G compound heterozygous state in HFE hemochromatosis: molecular dynamics and biochemical studies. Cézard C, Rabbind Singh A, Le Gac G, Gourlaouen I, Ferec C, Rochette J. Blood Cells Mol Dis 52 27-34 (2014)
  201. Comment Effects of iron and HFE mutations on response to therapy in chronic hepatitis C: an ironic interaction? Alexander J, Kowdley KV. Gastroenterology 131 1635-1638 (2006)
  202. Failure to detect synergy between variants in transferrin and hemochromatosis and Alzheimer's disease in large cohort. Vance E, Gonzalez Murcia JD, Miller JB, Alzheimer's Disease Genetics Consortium (ADGC), Staley L, Crane PK, Mukherjee S, Kauwe JSK. Neurobiol Aging 89 142.e9-142.e12 (2020)
  203. HFE Variants and the Expression of Iron-Related Proteins in Breast Cancer-Associated Lymphocytes and Macrophages. Marques O, Rosa A, Leite L, Faustino P, Rêma A, Martins da Silva B, Porto G, Lopes C. Cancer Microenviron 9 85-91 (2016)
  204. Iron beware: a common HFE gene polymorphism may prevent the accurate molecular diagnosis of homozygous hemochromatosis in low-risk, but not high-risk groups. Press RD. Hepatology 31 540-542 (2000)
  205. Mathematical modeling of mutant transferrin-CRM107 molecular conjugates for cancer therapy. Yoon DJ, Chen KY, Lopes AM, Pan AA, Shiloach J, Mason AB, Kamei DT. J Theor Biol 416 88-98 (2017)
  206. The functional significance of E277K and V295A HFE mutations. Silva B, Martins R, Proença D, Fleming R, Faustino P. Br J Haematol 158 399-408 (2012)
  207. The soluble form of HFE protein regulates hephaestin mRNA expression in the duodenum through an endocytosis-dependent mechanism. Silva B, Ferreira J, Santos V, Baldaia C, Serejo F, Faustino P. Biochim Biophys Acta 1842 2298-2305 (2014)
  208. Letter Correction to Bastin et al (1998). Townsend A. Br J Haematol 121 196-197 (2003)
  209. Haemochromatosis. Crawford DH, Ramm GA. Trends Endocrinol Metab 10 14-17 (1999)
  210. Hemochromatosis simulating rheumatoid arthritis: a case report. Barbosa FB, Callegari A, Sarinho JC, Lucena J, Casagrande R, de Souza BD. Rev Bras Reumatol 54 62-64 (2014)
  211. Hereditary hemochromatosis--sometimes having a real complex can be a good thing. Rouault TA. Hepatology 28 890-891 (1998)
  212. Renal transplantation and evolution of hemochromatosis: a clinical case report. Jorge C, Branco P, Domingos F, Gaspar A, Lebre L, Machado D. Transplant Proc 32 2613-2614 (2000)
  213. Therapeutic complications in a patient with high-risk acute lymphoblastic leukemia and undiagnosed hereditary hemochromatosis. Balagtas JM, Dahl GV. Pediatr Blood Cancer 58 101-103 (2012)
  214. Transferrin-modified chitosan nanoparticles for targeted nose-to-brain delivery of proteins. Gabold B, Adams F, Brameyer S, Jung K, Ried CL, Merdan T, Merkel OM. Drug Deliv Transl Res 13 822-838 (2023)
  215. Comment Utility of genotyping in diagnosis of genetic haemochromatosis. Crawford DH, Fletcher LM. J Gastroenterol Hepatol 14 401-402 (1999)
  216. [HFE, a MHC class Ib molecule that regulates iron metabolism]. Rohrlich PS, Kanellopoulos J, Lemonnier FA. Med Sci (Paris) 22 24-26 (2006)
  217. Caprine arthritis-encephalitis virus-infected goats can generate human immunodeficiency virus-gp120 cross-reactive antibodies(1). Louie KA, Dadgari JM, DeBoer BM, Weisbuch H, Snow PM, Cheevers WP, Douvas A, McMillan M. Virology 315 217-223 (2003)
  218. Cytokine and Gene Expression Profiling in Patients with HFE-Associated Hereditary Hemochromatosis according to Genetic Profile. Grønlien HK, Christoffersen TE, Nystrand CF, Garabet L, Syvertsen T, Moe MK, Olstad OK, Jonassen CM. Acta Haematol 144 446-457 (2021)
  219. Engineering Peptide Inhibitors of the HFE-Transferrin Receptor 1 Complex. Goncalves Monteiro D, Rishi G, Gorman DM, Burnet G, Aliyanto R, Rosengren KJ, Frazer DM, Subramaniam VN, Clark RJ. Molecules 27 6581 (2022)
  220. Hereditary Hemochromatosis and Iron Metabolism. Carlson J, Olsson S. EJIFCC 13 31-38 (2001)
  221. Normal and dysregulated crosstalk between iron metabolism and erythropoiesis. Ginzburg Y, An X, Rivella S, Goldfarb A. Elife 12 e90189 (2023)


Quick links